In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

AvenCell Therapeutics announces that the European Medicines Agency has approved its clinical trial application for AVC-201, a novel CRISPR-edited and...

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...

Researchers in the U.S. recently shed much needed light on the molecular mechanisms underpinning T cell exhaustion, revealing an epigenetic regulator...